BBR Partners LLC Sells 4,280 Shares of AbbVie Inc. $ABBV

BBR Partners LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 7.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 54,244 shares of the company’s stock after selling 4,280 shares during the period. AbbVie makes up about 0.6% of BBR Partners LLC’s holdings, making the stock its 17th largest holding. BBR Partners LLC’s holdings in AbbVie were worth $10,069,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Vestmark Advisory Solutions Inc. lifted its position in AbbVie by 84.3% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 38,888 shares of the company’s stock worth $8,148,000 after acquiring an additional 17,788 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in AbbVie by 42.7% during the first quarter. Kovitz Investment Group Partners LLC now owns 93,218 shares of the company’s stock valued at $19,531,000 after acquiring an additional 27,890 shares during the period. Finally, Azimuth Capital Investment Management LLC grew its position in shares of AbbVie by 0.3% in the first quarter. Azimuth Capital Investment Management LLC now owns 108,098 shares of the company’s stock valued at $22,649,000 after purchasing an additional 339 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Down 0.2%

ABBV opened at $223.45 on Friday. The company has a market capitalization of $394.92 billion, a P/E ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The firm’s fifty day moving average price is $227.25 and its two-hundred day moving average price is $209.59. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the firm earned $3.00 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Wells Fargo & Company upped their price target on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Evercore ISI boosted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $244.55.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.